FDA Slaps Genzyme With Refuse to File for Lemtrada
By Catherine Shaffer
Tuesday, August 28, 2012
The FDA surprised Genzyme Corp., a Sanofi company, with a refuse to file letter for its supplemental biologics license application (sBLA) for Lemtrada (alemtuzumab) as a treatment for relapsing multiple sclerosis (MS).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.